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Abstract
This paper studies the design of health insurance with ex post moral hazard, when there
is imperfect competition in the market for the medical product. Various scenarios, such
as monopoly pricing, price negotiation or horizontal differentiation are considered. The
insurance contract specifies two types of copayments: an ad valorem coinsurance rate
and a specific (per unit) copayment. By combining both copayment rates in an adequate
way the insurer can effectively control the producer price, which is then set so that the
producer’s revenue just covers fixed costs. Consequently, a suitable regulation of the
copayment instruments leads to the same reimbursement rule of individual expenditures
as under perfect competition for medical products. Additional rationing of coverage
because of imperfect competition as advocated by Feldstein (1973) is thus not necessary.
Interestingly the optimal policy closely resembles a reference price mechanism in which
copayment rates are low (possibly negative) and coinsurance rates are high.
JEL Codes: I11, I13, I18.
Keywords: ex post moral hazard, health insurance contracts, copayments, imperfect
competition.
1 Introduction
According to conventional wisdom, the level of health insurance provided by a compet-
itive insurance industry is “too generous” when there is imperfect competition in the
market for medical products. This property has been first documented in the classical
paper by Feldstein (1973), and more recently by Feldman and Dowd (1991). A direct
implication of this property is that the regulator should restrict insurance coverage1
or/and encourage price competition.2 This paper challenges the first view, namely that
insurance coverage should be lower under imperfect than under perfect competition for
medical products. Instead, we show that when there is imperfect competition, a suitable
regulation of copayment instruments would eventually lead to the same reimbursement
rule of individual expenditures as under perfect competition for medical products. In
other words, while full insurance is typically not desirable, imperfect competition in the
market for medical products does not require an extra reduction in insurance coverage,
as long as the reimbursement scheme is properly designed.
The need to restrict health insurance coverage arises because of the so-called ex
post moral hazard in health care systems. This phenomenon refers to the increase of
health expenditures, which is due to health insurance coverage; Arrow (1963) and Pauly
(1968). Expenditures increase for two reasons. First, health insurance typically reduces
the share of health expenditures that is paid by policyholders. This tends to increase
total expenditures, as long as patients’ demand is not totally price inelastic. Second,
health care providers, which evolve in an imperfect competition setting, respond to this
higher demand by increasing prices. To mitigate this moral hazard problem, insurance
coverage is typically less than 100%. Copayments for medical products take various
forms in developed countries. On top of (possibly capped) deductible, patients may
face a copayment rate (a fixed amount per unit of the medical good consumed)3 and/or
a traditional coinsurance rate (a proportion of the medical bill). Very often, public or
private insurance plans combine these two kinds of copayments.
1See Varithianathan (2006), for a formal analysis of this issue.
2See, e.g., Gaynor et al. (2000).
3Exemples of copayments are payment per drug prescription, per pills, per doctor’s visit, per hospi-
tal’s admission etc...
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We characterize the “optimal” reimbursement of medical goods under ex post moral
hazard, and imperfect competition in the providers’ market. The novelty of this paper
is that the insurer may use simultaneously two types of instruments that are widely used
in practice: a linear ad valorem copayment rate (also called coinsurance rate), which is
a share of expenditure for the health care product, plus a specific (per unit) copayment
rate which is proportional to the quantity of the health care product consumed. Doing
this, we build on the framework developed by Zeckhauser (1970) and later by Besley
(1988), but we relax the assumption that the price of medical services is exogenously
fixed. Instead, we study health insurance design when the price of medical products is
determined in an imperfectly competitive market. We consider various scenarios, such
as monopoly pricing, price negotiation or horizontal differentiation with free entry.
Our model consists of a three stage game. In a first stage, the insurer chooses the
levels of the premium and the two out-of-pockets rates. In a second stage, the price of
medical good is determined. Finally, in a third stage, the state of nature is revealed and
patients buy the quantity of medical care products to maximize their utility given the
state of their health and (net) prices.
We show that the insurer can always extract the full surplus of the monopolist by
using an appropriate combination of coinsurance and copayment. In other words, under
this reimbursement policy, the producer’s net revenue is just sufficient to cover the
fixed cost of the medical product. This remains true mutatis mutandis in the different
competitive scenarios we consider. In either case, the insurer can restore a second-best
reimbursement rule corresponding to the one used under perfect competition. This
combination involves the lowest possible level of copayment rate (possibly negative)
associated with the highest possible level of coinsurance rate such that the participation
constraint of health providers is binding.4 As a result, the optimal policy resembles
very much the reference price mechanism in which copayment rates are very low and
effectively negative, while coinsurance rates are high. To be more precise, the idea of
reference pricing is that patients are required to pay the difference between the actual
4 In the Bertrand competition case with free entry, the level of this profit is endogenous to the
reimbursement system (see Subsection 6.3.2).
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price received by the supplier and the insurer’s contribution limit (the reference price).
As such, in its extreme form, reference pricing can be seen as a combination of a 100%
coinsurance rate combined with a negative copayment rate (equal to minus the reference
price).
This result and the conditions on which it relies are particularly interesting as it
sheds light on some of the issues that are at the heart of the American health care
debate. The Obama administration has recently given the go-ahead for insurers and
employers to use reference prices as cost-control strategy in the health sector.5 Our
results provide support for this policy. However, for our policy to be fully effective,
both instruments have to be regulated; controlling the average reimbursement rate as
envisioned by the Affordable Care Act is not enough. Instead the type of contract
and the form of the copayments would have to be regulated. Such a system would
resemble that of so called “Social Health Insurance” countries in Europe like Germany,
The Netherlands or Switzerland where insurance companies offer standardized contracts
but compete in premiums. Our results imply that a suitable regulation of the forms of
copayment would ultimately solve the problem of excessive insurance without altering
the level of individuals protection.
In addition to the literature already mentioned, our paper is related to a recent
article by Lakdawalla and Sood (2013). These authors also show that a second-best
insurance scheme can be restored when the medical product is sold by a monopolist.
However, their result holds only when the monopolist can choose both quantity and price.
In this case, everything works exactly as when the monopolist can charge a two-part
tariff which leads to a market price equal to marginal cost, while surplus is extracted
through the fixed part. In our framework, there is no need that the monopolist chooses
both quantity and prices; put differently, the policy we describe is effective under linear
pricing; no two-part tariffs are needed.
Finally our paper is also related to the literature on tax incidence under imperfect
5Since the success of CalPERS (California Public Employees’ Retirement System) in implementing
reference pricing for hip and knee replacement (see Robinson and Brown, 2013), the Mercer benefits
consulting firm reported that 12% of the largest employers were using reference pricing in 2013, nearly
twice the 7% who relied on it in 2012.
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competition which has been developed in public finance.6 In particular this literature
compares the respective properties of ad valorem taxes and specific taxes and shows
that the former is in general welfare superior. To be more precise, the ad valorem tax
yields more tax revenue for any given output level. Intuitively this result arises because
the ad valorem tax is effectively equivalent to a specific tax supplemented by a profit
tax, the latter raising revenue without affecting quantity. Most closely related to our
analysis is probably the paper by Delipalla and Keen (1992). They establish the welfare
dominance of ad valorem taxes in a Ramsey framework where the government has to
finance a given level of public expenditure and has to rely only on consumption taxes.
However, they restrict all taxes to be positive so that producer prices cannot be fully
controlled. Recall that our result typically requires a negative copayment rate. In the
health sector this is a realistic option as the reference pricing example shows, while
otherwise taxes are most often restricted to be positive.
In the next section we present the model. Section 3 studies the benchmark case
with perfect competition in the market for medical products. Next, Section 4 examines
the case of a monopoly. Section 5 analyzes the optimal insurance scheme when the
insurer and the monopoly bargain over the producer price. Finally, Section 6 studies the
optimal contract when different variants of the medical product are sold in a horizontally
differentiated oligopoly. We use a setting based on the discrete choice approach, without
and with free entry.
2 The Model
A mass 1 of agents are endowed with an identical income . They each face a risk
distributed over Θ ≡ £ ¤ to become of type . The density and distribution functions
of  are respectively given by () and (). Individuals maximize their expected utility.
Their preferences are represented by a Von-Neumann-Morgenstern utility function  ≡
(  ), where  denotes the consumption of a numeraire composite good, while 
represents the consumption of a medical product (for instance a prescription drug) the
(producer) price of which is denoted by  . The function  is strictly increasing and
6See Myles (1995), ch.11 for a detailed survey.
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strictly concave in its  and .
The consumption of  may be covered by a health insurance scheme, which can be
seen as a partial subsidy to  . The copayment can take two forms. The first type
of copayment is “ad valorem” in the sense that the out-of-pocket amount paid by the
individual is a share of total expenses on the medical product, namely . Let  denote
the “ad valorem” copayment rate, which in the health insurance literature is often
referred to as “coinsurance” rate. The second type of copayment is “specific” so that
the out-of-pocket payment is simply proportional to the quantity ; this corresponds to
what the health economics literature refers to as “copayment” rate. Let  denotes this
copayment rate. As a result, the net (or consumer) price of the medical product is given
by
˜ = +  (1)
Observe that we do not restrict  to be positive nor  to be less than one. As an
example, consider the case in which   0 and  = 1. This special case represents the
reference price mechanism in which patients are entitled to pay the difference between
the producer price  and the reference price (here equal to −). To buy this insurance
protection, policyholders pay a premium . In state , the consumption of the composite
good is thus given by
 =  −  − ˜  (2)
where  denotes the consumption of the medical product in state , and the expected
utility can be rewritten as
 =
Z

( −  − ˜   )()
where  denotes the expectation operator over Θ.
2.1 Timing
Decisions are made in three stages according to the following timing. First, the insurer
chooses the triplet (  ). Second, the gross price  (and thus the net price ˜ ) is
determined by the market of the medical product. Finally, the state  is realized and
each individual of type  chooses . We consider different scenarios which differ mainly
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in the underlying specification of stage 2, that is how the market for the medical product
is represented. These include perfect competition, monopoly, differentiated oligopoly
as well as a bargaining procedure over the price.7 In either case, we determine the
“subgame perfect” equilibrium and solve the game by backward induction.8
The optimal health insurance contract is determined by the following problem
max  =
Z

( −  − ˜   )() (3)
s.t.  =  −
³
 − ˜
´
 ≥ 0 (4)
where the constraint (4) states that , which is equal to the premium minus expected
coverage of expenses on the medical product, must be positive or equal to 0. In a
subgame perfect solution, the insurance provider anticipates the equilibrium induced
by its strategy in the subsequent stage: the levels of  in stage 3 and the producer
price  in stage 2.
2.2 The individual problem
As policyholders are price takers, the solution to stage 3 does not depend on the scenario
adopted for the market of the medical product, i.e. the determination of its price. Once
the state of nature  is revealed policyholders choose their consumption of  that solves
max ( −  − ˜   )
taking ˜ and  as given. Assuming an interior solution yields the following first-order
condition for all  ∈ Θ
˜ (˜ − ˜   ) =
(˜ − ˜   )
  (5)
where ˜ = − represents the income net of the premium paid. Equation (5) simply de-
fines the standard Marshallian demand ∗
³
˜  ˜
´
, as a function of the (consumer) price
and the income. Aggregate (expected) demand is denoted by ∗
³
˜  ˜
´
= ∗
³
˜  ˜
´
.
7 In the differentiated oligopoly case, stage 3 is also modified to account for consumers preferences
over the differentiated medical products.
8Even though stage 2 is not always explicitely as a “proper” game (for instance in the case of perfect
competition).
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3 Optimal insurance under perfect competition
Assume first that there is perfect competition in the market of the medical product,
with firms having a constant marginal cost equal to . The producer price  of the
medical product is then equal to  and the problem of the insurance provider amounts
to choosing
³
 ˜
´
that solves
max
˜
 =
Z


h
 −  − ˜ ∗
³
˜  ˜
´
 ∗
³
˜  ˜
´
 
i
() (6)
s.t.  =  −
³
 − ˜
´
∗
³
˜  ˜
´
 () ≥ 0 (7)
Since the producer price is given, it immediately follows that coinsurance or copayment
rates are equivalent. Only ˜ = +  matters and all combination of  and  that bring
about a given level of ˜ yields exactly the same outcome. This does not come as a
surprise! It is perfectly in line with the standard result, obtained in tax incidence, that
ad valorem and specific taxes are equivalent under perfect competition. And as far as
their impact on consumers are concerned, copayment rates are exactly similar to taxes.9
Appendix A shows that the optimal reimbursement rate is determined by³
 − ˜
´
˜ =
³
 − ˜
´
˜ = −
cov (∗ Λ)
∗∗
 (8)
where ∗ is the price elasticity of the compensated (Hicksian) demand for  while Λ is
defined by
Λ =

 −
³
˜ − 
´ ∗
˜ =
1

∙
 − 
³
˜ − 
´ ∗
˜
¸
 (9)
where  is the multiplier associated with the insurance provider’s revenue constraint (7).
The terms Λ is the counterpart to the “net social marginal utility of income” used in
taxation models; see Diamond (1975). The expression in brackets in the last term of (9)
represents the expected marginal utility gain of a marginal decrease in the premium.10
The term cov(∗ Λ) measures the benefits of providing insurance. It is positive when
policyholders with a higher , who consume a higher level of  have a larger marginal
utility of income. This is necessarily true when the illness causes a monetary cost as is
9Similarly, the net revenue of the insurer, , plays the same role as tax revenue in taxation models.
10Dividing by , the shadow cost of the insurer’s net revenue, converts utility into monetary terms.
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often assumed in the health economics literature. With a more general representation of
the impact of illness on utility, the covariance term is in principle ambiguous. However,
we shall concentrate on the case where it is positive because otherwise health insurance
is not desirable. This rule expresses the optimal reimbursement rate (LHS) as being
a trade-off between risk sharing (the numerator in the RHS) and efficiency loss due to
moral hazard ex post (the denominator in the RHS).11
In the remainder of the paper, we consider alternative models of the market for the
medical product and determine the optimal policy of the insurance provider in each case.
Section 4 considers the case of an (unregulated) monopoly. In Section 5 we continue to
assume that there is a single producer but that the price is determined through a Nash
bargaining process between the regulator and the seller. Finally Section 6 considers a
model of Bertrand competition with  profit maximizing producers selling horizontally
differentiated products.
4 Profit maximizing monopoly
4.1 Price formation
Assume that the medical product is supplied by a profit maximizing monopoly. Its
profit function is given by
Π = ( − )− 
where  and  respectively denote the marginal and the fixed cost, which includes all
the sunk costs incurred during the development of the medical product. Aggregate
(expected) output  is given by  = ∗
³
˜  ˜
´
. Rewriting the profit in terms of the
consumer price ˜ defined by (1) yields
Π = 1
³
˜ − ˜
´
∗
³
˜  ˜
´
−  (10)
11Since copayment rates are formally equivalent to taxes, it is not surprising that this rule is very
similar to the many-person Ramsey rule derived by Diamond (1975). In taxation models, the trade-
off is between redistributional benefits and deadweight loss. In our insurance model, “redistribution”
occurs between states of nature and is referred to as risk sharing, while the efficiency loss, measured
by the impact of ex-post moral hazard, is essentially equivalent to the expected deadweight loss of
reimbursement rates.
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where ˜ = + . Recall that at this stage ,  as well as , and therefore ˜ = − are
given. Expression (10) shows that the problem of the monopoly amounts to choosing the
net price ˜ . The monopoly’s problem is then to maximize its profits given by equation
(10) with respect to ˜ . This yields the following pricing rule
˜ − ˜
˜ =
1
||  (11)
where || =
³
˜ 
´³
˜
´
 1 denotes the (marshallian) price elasticity of  with
respect to ˜ . Observe that while equation (11) provides a closed form solution only
when  is constant (which we do not assume), it is valid for any demand function.12 For
future reference, notice that the RHS of this expression does not depend on  nor ; the
two copayment parameters only appear on the LHS, through ˜ = + . Consequently,
we can solve (11) with respect to e for a given level of ˜ which yields
˜ = ˜
µ
1− 1||
¶
 (12)
This expression shows that the insurance provider can effectively bring about any level
of ˜ by setting ˜ at the appropriate level.
Let Π∗ ( ) denote the profit the monopolist achieves in the equilibrium of the health
care market. The monopolist is entering the market only as long as its “participation
constraint” is satisfied
Π∗ ( ) ≥ 0 (13)
so that its revenues are sufficient to cover all its cost, including the fixed cost. Profit
is zero when the total mark-up (over marginal cost) is just sufficient to cover the fixed
cost  .
Before studying the general problem we study the optimal insurance scheme when
only one of the instruments is available. In these two subsections (and only there), we
shall assume for simplicity that demand elasticity, , is constant. Interestingly enough,
these solutions correspond to the level of insurance protection when the regulator wants
to ration the provision of insurance as advocated by Feldstein (1973). As will be clear
later, this rationing solution is far from being optimal.
12As long as there is an interior solution.
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4.2 The optimal coinsurance reimbursement rule
Assume first that the insurance provider can only use the coinsurance rate . In other
words, a fraction (1 − ) of the cost of the medical product is reimbursed so that e =
(1− ) . Setting  = 0, its problem is now:
max  =
Z


h
 −  − ˜∗
³
˜  ˜
´
 ∗
³
˜  ˜
´
 
i
() (14)
s.t.  =  −
³
 − ˜
´
∗
³
˜  ˜
´
 () ≥ 0 (15)
where with ˜ = , the monopoly pricing rule (11) implies
˜ =  (1− 1 ||) and  =  (1− 1 ||)  (16)
When  is constant, the producer price  is not affected by the insurance scheme.
The problem of the insurance provider is thus the same as under perfect competition
except that  , which was equal to  under perfect competition has to be replaced by
 as defined by (16). From equation (8) the optimal reimbursement rate is then given
by
 − ˜
˜
¯¯¯¯
¯=0 = −
cov
¡∗ Λ¢
∗∗
 0 (17)
In words, when the covariance term is positive so that the provision of health insurance
is desirable, we get a positive (but lower than 1) coinsurance rate , the level of which
is determined by the trade-off between risk sharing and ex-post moral hazard described
in Section 3.
4.3 The optimal specific reimbursement rule
Assume now that the insurance provider can only use a specific reimbursement rate. To
provide health insurance, the copayment rate  must then be negative. Setting  = 1,
the insurance provider’s problem is now
max  =
Z


h
 −  − ˜∗
³
˜  ˜
´
 ∗
³
˜  ˜
´
 
i
() (18)
s.t.  =  −
³
 − ˜
´
∗
³
˜  ˜
´
 () ≥ 0 (19)
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where with ˜ = , the monopoly pricing rule (11) implies
˜ = (+ )  (1− 1 ||) and  = ( ||+ )  (1− 1 ||)  (20)
Unlike with a coinsurance rate, the monopoly price now depends positively on the
copayment rate level, . As a result, a higher specific reimbursement, that is a lower
level of , decreases the monopoly price.
Assuming again that || is a constant, we show in Appendix B that the optimal
reimbursement rate is now given by
 − ˜
˜
¯¯¯¯
¯=1 = −
1
||
³
˜  ˜
´
+ cov
¡∗ Λ¢
∗∗
 0 (21)
Compared to the coinsurance and perfect competition case, we now have an extra term
in the numerator, namely 
³
˜  ˜
´
 || which is positive so that it tends to increase
the reimbursement, i.e., decrease . Recall that a decrease in  reduces the producer
price, which represents a second positive effect, on top of the provision of insurance. The
price effect is stronger the less elastic is demand for medical products, which explains
why || appears in the denominator of the extra term.13
4.4 The optimal health insurance contract with multiple instruments
We now return to the case where the insurance provider can use both instruments. Recall
that we do not restrict  to be positive nor  to be less than one. Before determining
the optimal level of the instruments we shall examine if and how the two instruments
have to be combined.
To do this we start from an arbitrary reimbursement policy ( ) and consider a
variation  = −, with   0. Since ˜ =  + , this variation leaves ˜ unaffected.
By equation (11), ˜ thus 
³
˜  ˜
´
are not affected either, so that the indirect
utility remains the same. Rewriting (11) in terms of the producer price  yields¡+ ¢µ1− 1||
¶
= ˜
13Differentiating (20) yields

 =
1
||− 1  0
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where the demand elasticity is constant as long as the consumer price ˜ is given. The
variation  = − thus implies


¯¯¯¯
˜=constant
= − −   0
Consequently, the considered variation lowers the producer price which, by the budget
constraint in (4) decreases the insurance provider’s expenses without affecting its ob-
jective function. In words, by reducing  and increasing , according to  = −, the
insurance provider can reduce the producer price and profit while leaving the consumer
price unaffected. This in turn immediately implies that the optimal policy (∗ ∗) must
be such that the monopolist’s participation constraint is binding i.e., Π∗(∗ ∗) = 0.
Consequently, the budget constraint of the insurance provider
 = −
³
˜ − 
´
∗(˜  ˜) = −
³
˜ − 
´
∗(˜  ˜)+¡ − ¢∗(˜  ˜) ≥ 0
can be written as  +
³
˜ − 
´
∗(˜  ˜) −  , which is the same as under perfect
competition except that we have to account for the fixed cost of the monopolist.
Therefore the problem of the insurance provider can be decomposed into two stages.
First, we can solve the insurance provider’s problem with ( e ) as decision variables
exactly as under perfect competition, except that  has to be included in the budget
constraint. Recall that since the RHS of equation (11) and thus also of (12) is indepen-
dent of ˜, the insurance provider can effectively “choose” the level of ˜ . This stage
of the insurance provider’s problem is then given by
max
˜
 =
Z


h
0 −  − ˜∗(˜  ˜) ∗(˜  ˜) 
i
() (22)
s.t.  +
³
˜ − 
´
∗(˜  ˜)−  ≥ 0 (23)
Since this is the same problem as under perfect competition (except that we require
 ≥  rather than  ≥ 0), the optimum is described by equation (8) together with the
budget constraint (23). The solution to this problem yields the optimal consumer price
˜∗ and from equation (12) the optimal level of e∗ = + .
To obtain the full solution to the insurance provider’s problem it is then sufficient
to set the levels of ∗ and ∗ such that
∗ + ∗ = e∗ (24)
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and
Π∗(∗ ∗) = 0
Figure 1 illustrates this reasoning. The dashed line with slope− represents equation
(24); and shows the combination of  and  that yields e∗. The downward sloping curves
represent the iso-profit curves. Their slope is given by
−
Π∗(∗∗)

Π∗(∗∗)

= −
³
 +
³
˜∗ − 
´

´
 (25)
where we have differentiated equation (10) by making use of the envelope theorem.
Observe that the iso-profit curves are steeper than the line representing equation (24);
their slope exceeds  (in absolute value). The bold curve corresponds to a profit level of
zero. On the south west of the bold curve, profits are negative while they are positive
in the north east. The solution is given by the intersection of this iso-profit curve and
the straight line. Intuitively one can think of this as moving along the line towards the
point where profits are exactly zero.
5 Regulated monopoly: price bargaining
Assume now that when a new medical product is accepted for introduction in the mar-
ket, its price is set by a bargaining process between the regulator and the producer.
This process is represented by a Generalized Nash Bargaining Solution, with respective
bargaining weights of  for the regulator and of (1− ) for the producer. It represents
the second stage of our three stage game. When the bargaining takes place,  and  are
already set. Recall that in stage 1 the insurance provider anticipates the equilibrium
of the subsequent stages induced by its strategy. The outside option (or threat point)
corresponds to the situation where the medical product is not sold at all. The regula-
tor objective is to maximize the consumer’s expected utility while the firm maximizes
profits. The outside option yields a given level of utility 0 to the consumer which
corresponds to the expected utility when  = 0 for all , while the producer’s profit is
equal to − . The difference between the producer’s profit and its threat point level is
13
Figure 1: The optimal combination of co-insurance and co-payment.
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thus equal to:
( − ) ( ) = [( − ) ( )−  ]− (− )
The solution to the bargaining process is then given by
 = argmax ( ( )−0)
 (( − ) ( ))1− 
This problem is equivalent to determining ˜ such that
˜ = argmax
˜
³

³
˜
´
−0
´ µ1

³
˜ − ˜
´

³
˜
´¶1−

Differentiating this expression and rearranging the first-order condition yields³
˜ − ˜
´
˜ =
1

(1−)
((˜))
(˜)−0 − 
 (26)
When solving the full game, this equation replaces its counterpart in the unregulated
case, namely (11). Interestingly, the RHS of equation (26), like that of equation (11)
does not depend on ˜. Consequently one can proceed in exactly the same way as in
section 4.4, so that the program of the insurer continues to be the one stated by (22)—(23)
and we are back to the second-best rule stated by (8).
To sum-up, the solution is exactly the same whether or not the monopoly is reg-
ulated; profit maximization and price bargaining give the same result. This is true,
whatever the bargaining weight of the firm, which may appear surprising at first. The
key to understanding this is that the insurance provider’s reimbursement policy is a
“very powerful” tool since it can bring the producer to a zero profit level in any case.
6 Differentiated oligopoly with  firms: discrete choice
approach
To study this setting, we have to redefine not only Stage 2 but also Stage 3 of our game.
Specifically we have to redefine the consumer’s preferences to account for the possibility
to choose between  variants of a horizontally differentiated medical product. Suppose
now there are  ≤  firms in the market indexed by  = 1 . Firms are ranked
by their fixed cost  ,  1 ≤  ≤   ≤  +1 ≤   . In order to make the problem
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tractable, we now assume that a patient  ∈ Θ consuming  units from producer 
derives a utility:
 = 
¡¢+  ¡ ¢−  ¡˜¢ 
where ˜ ∈  measures a random cost of consuming product  over Θ . The  func-
tion represents the health status of the patient which is assumed to be separable from
the utility of consumption14. The random variables ˜ are iid and their (marginal)
distribution is exponential with a mean normalized to 1, so that their cdf is repre-
sented by  () = 1− exp (−). We further assume that the cost function is defined by
 () = exp (), where   0measures how substitutable the horizontally differentiated
products  are, with a lower  implying a higher degree of substitution between the
products.15
6.1 The individual problem reconsidered
We assume that the  variants of the medical product are consumed in a mutually
exclusive way, i.e. each patient of type  consumes a single product . This property
applies to many markets for medical products. For instance patients often use a single
drug selected amongst different molecules that treat the same disease;  measures in
this case possible side effects caused by drug  on patient of type . Patients may also
choose hospitals or specialists with respect to the geographical distance or the kind of
treatment they offer, etc.
Individual demand conditional on consuming variant ,  is defined by
 = argmax 
³
 −  − ˜ 
´
+  ¡ ¢ 
where ˜  = +  .
The first-order condition is given by
−˜ 0
³
 −  − ˜ 
´
+
 ¡ ¢
˜  = 0
which implicitly defines  ≡ 
³
˜  ˜
´
, the (conditional) demand of individual  for .
An individual of type  choosing variant  obtains an indirect utility   ≡ 
³
˜  ˜
´
=
14This assumption is compatible with the findings of Finkelstein et al. (2013).
15For a survey of discrete choice product differentiation models, see Anderson et al. (1992).
16

³
˜  ˜
´
−  ¡˜¢ where  ³˜  ˜´ ≡ ³˜ − ˜ ´ +  ¡ ¢ denotes the indirect
utility gross of the random cost of consuming variant .
An individual of type  chooses the variant  that solves
max=1
© ª 
In a symmetric equilibrium where ˜  = ˜ for every  ∈ (1 ), each individual of type
 minimizes the loss so its indirect utility function writes:
  = 
³
˜  ˜
´
−min 
¡˜¢  (27)
As a result, at a symmetric equilibrium, the expected indirect utility function writes:
 = 
³
˜  ˜
´
−
½
min
£
exp˜
¤¾
= 
³
˜  ˜
´
−  − 
Observe that the number of variants  , has a direct positive impact on expected utility.
This makes sense within the context of medical products. As a larger diversity of
treatments becomes available, patients have more options when choosing the product
which has the smallest adverse effect. In addition, the number of variants also has an
indirect effect on utility because it affects the market price, the determination of which
we shall now study.
6.2 Equilibrium price
To determine the symmetric Nash equilibrium price, we have to determine the best-
response of producer , ˜ , to a price ˜ set by all other firms. Appendix C shows that
the expected demand for product  of individual  is given by

³
˜  ˜
´
= 
∞Z
0
exp (−)
³

³

³
˜  
´
− 
³
˜  
´´
+ exp ()
´−−1  (28)
and that the producer’s total demand is equal to

³
˜  ˜
´
= 
h

³
˜  ˜
´i

17
Differentiating this expression with respect to ˜  yields

˜  = 

³
˜  ˜
´
˜   (29)
Using (28) and rearranging shows that

³
˜  ˜
´
˜  =
1


˜  +
( − 1)
 +  


³
˜  
´
˜  
Using (29), Roy’s identity, and evaluating at ˜  = ˜ we obtain

³
˜  ˜
´
˜  = 
µ
−( − 1) + 
³

³
˜
´´2 0 () + 1 ˜
¶
 (30)
Each producer  maximizes its profit and solves
max
˜ 
Π = 1
³
˜  − ˜
´

³
˜  ˜
´
−  
The first-order condition is

³
˜  ˜
´
+
³
˜  − ˜
´  ³˜  ˜´
˜  = 0 (31)
Define 
³
˜
´
= (˜  ˜ ). In a symmetric equilibrium each producer has demand
(˜  ˜ ) = 
³
˜
´
 . Using (30) and rearranging shows that (31) can be rewritten as³
˜ − ˜
´
˜ =
1
(−1)
+ ˜


((˜))20()

(˜) − 
 (32)
where  is the price elasticity of . When solving the full game, this equation replaces
its counterpart in the monopoly case, namely (11) and defines ˜ as a function of ˜ and
 . Observe that the RHS of this expression, like that of equation (11) in the monopoly
case, and equation (26) in the bargaining case, does not depend on ˜.
The equilibrium profit of firm  is then given by
Π∗ ( ) = ( − )
³
˜
´
 −  
where ˜ is determined by (32), so that  follows from (1).
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6.3 The insurance provider’s program
There are  potential firms ranked and indexed in increasing order according to their
increasing fixed costs  1 ≤  ≤   ≤  +1 ≤   . We consider two different problems.
First, we assume that the number of active firms  is given. This is the short-run
problem. Second, in the long-run problem,  can also be chosen.
6.3.1 Short-run
In the short-run, the number of active firms and available variants of the medical prod-
ucts,  , is exogenously given. The reimbursement policy must be designed such that
all active firms make positive profits. In a symmetric equilibrium, firms differ only in
fixed costs so that it is the participation constraint of producer  which is binding. In
words, the active firm with the highest fixed cost realizes zero profits.
Recall that the RHS of equation (32) does not depend on ˜ and therefore one can
repeat the same reasoning as the one in Section 4.4. The participation constraint of
producer  will be binding so that the insurance provider’s program is
max
˜
Z

(0 −  − ˜ ∗(˜  ˜)) + 
³
∗(˜  ˜) 
´
()−  − 
s.t.  +
³
˜ − 
´
∗(˜  ˜)− ≥ 0
Again the second-best reimbursement rule (8) applies.
6.3.2 Long-run
For the sake of simplicity, we neglect the fact that  must be an integer and denote
by  () the sunk cost of firm  ≤  with  0 ()  0. There are two ways to
think about this long-run solution: either there is free-entry so that firms enter until
Π∗ ( ) = 0, or the insurance provider selects the  firms to be on the list of
the reimbursable medical products, which once again implies Π∗ ( ) = 0. Since
the insurance provider through its reimbursement policy effectively controls the prices,
both of these scenarios are equivalent. Either way, the insurance provider then solves
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the following problem
max
˜ 
Z

(0 −  − ˜ ∗(˜  ˜)) + 
³
∗(˜  ˜) 
´
()−  − 
s.t.  +
³
˜ − 
´
∗(˜  ˜)− () ≥ 0 (33)
The optimal interior solution is again characterized by (8), (33) and the additional first
order condition with respect to 
 () + 0 () =  ( − )2 
where  is the Lagrange multiplier associated to the insurance provider’s budget con-
straint. The left hand side represents the budgetary cost of an additional firm while
the right hand side represents the (monetary equivalent) expected marginal utility gain
brought about by the availability of an additional variant of the medical product.16
7 Conclusion
This paper has studied the design of health insurance under ex post moral hazard,
when there is imperfect competition in the market for the medical product. We have
considered various scenarios, such as a profit maximizing monopoly, price negotiation
or a horizontally differentiated oligogopoly with or without free entry. The insurance
contract specifies two types of copayments: an ad valorem coinsurance rate and a spe-
cific (per unit) copayment rate. By combining both copayment rates in an adequate
way the insurer can effectively control the producer price, which is then set so that the
producer’s revenue just covers fixed costs. This combination involves the lowest possible
level of copayment rate (possibly negative) associated with the highest possible level of
coinsurance rate such that the participation constraint of health providers is binding.
Consequently, a suitable regulation of the copayment instruments leads to the same
reimbursement rule of individual expenditures as under perfect competition for medical
products. Rationing coverage because of imperfect competition as advocated by Feld-
stein (1973) is thus not necessary. Interestingly the optimal policy closely resembles a
16An increase in  also affects  and . However, by the envelope theorem these induced variations
have no first-order effect on the insurer’s objective.
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reference price mechanism in which copayment rates are low (possibly negative) and
coinsurance rates are high. The enforcement of reference pricing is part of the health
care reform advocated by the Obama administration. Our results do provide support
for this policy. However, for our policy to be fully effective, both instruments have to be
regulated; controlling the average reimbursement rate as envisioned by the Affordable
Care Act is not enough. Instead the type of contract and the form of the copayments
would have to be regulated.
To keep our model tractable we had to neglect some important aspects. These
include first and foremost the quality of health care products. As our results imply full
extraction of the producers’ surplus, one might object that the policy we characterize
may undermine the overall quality of health care services. This objection is only justified
in part because the fixed cost can be interpreted as including a “fair” rate of return on
the research and development investments incurred by the producers. Still, this leaves
open the issue of the “optimal” investment in medical research and more general the
determination of the appropriate quality of medical products. When these aspects are
accounted for, it might be the case that the optimal policy involves a tradeoff between
the extraction of producers surplus (rents) and the level of quality of health care products
driven by innovations. Introducing quality competition in a setting with ex post moral
hazard is a challenging endeavour which is on our agenda for future research.
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Appendix
A Derivation of equation (8)
Denoting  the Lagrange multiplier associated to the insurance provider’s budget con-
straint, the FOCs with respect to ˜ and  are respectively given by
−   + 
h
(˜ ) +
³
˜ − 
´
0(˜ )
i
= 0 (34)
−   + 
∙
1 +
³
˜ − 
´ 

¸
= 0 (35)
Multiplying (35) by  = (˜ ) and subtracting (34) yields:
  −

 − 
³
˜ − 
´
 
∗
˜ + 
³
˜ − 
´
  = 0 (36)
Denoting the compensated (Hicksian) demand by  and substituting the Slutsky equa-
tion

˜ =
∗
˜ + 
∗
∗
 (37)
into equation (36) yields:
  −

 − 
³
˜ − 
´
 

˜ −

³
˜ − 
´
 
∗
 + 
³
˜ − 
´
  = 0
Using the definition of Λ in expression (9), this can be rewritten as
cov
³
Λ
´
=
³
˜ − 
´
 

˜ 
or ³
˜ − 
´
˜ =
cov
¡Λ¢
  (38)
where ∗ =
³
˜ 
´³
˜
´
. Multiplying by −1 then yields expression (8).
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B Derivation of equation (21)
Using (20), problem (18)—(19) can be written as
max  =
Z

( −  − ˜∗
³
˜  ˜
´
 ∗
³
˜  ˜
´
)()
s.t. :  + ∗
³
˜  ˜
´
≥ 0
Assuming that || is a constant and denoting  the Lagrange multiplier associated to
the insurance provider’s budget constraint, the first-order conditions with respect to 
and  are respectively given by:
− 1
1− 1||
∗  + 
"
∗(˜ )−
³
 − ˜
´ 1
1− 1||
∗
˜
#
= 0 (39)
−   + 
∙
1−
³
 − ˜
´ ∗

¸
= 0 (40)
Multiplying (39) by (˜ ) and subtracting (40) yields:
1
1− 1||
  −

 +
1
1− 1||
³
 − ˜
´
 
∗
˜ −
³
 − ˜
´
  = 0
(41)
Using the Slutsky equation (37) and rearranging yields
1
1− 1||
∗  −
∗  + 
1
1− 1||
³
 − ˜
´
 

˜ +
 1
1− 1||
³
 − ˜
´
∗ 
∗
 − 
³
 − ˜
´
∗ 
∗
 = 0
Multiplying by 1 (1− 1 ||) and using the definition of Λ in expression (9), this can
be rewritten as:
cov (∗ Λ) + 1||
⎛
⎝
∗  + 
³
 − ˜
´
∗ 
∗

⎞
⎠ =
³
˜ − 
´
 

˜ 
Using (39) yields
cov (∗ Λ) + 1||
∗ =
³
˜ − 
´
 

˜ 
so that ³
˜ − 
´
=
1
||∗ + cov (∗ Λ)
 ˜

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Multiplying by −1, dividing by ˜ and using the definition of ∗ then yields expression
(21).
C Derivation of equation (28)
The probability that variant  is chosen by a patient  is determined by
Pr
µ

³
˜  
´
−  ¡¢ ≥  ³˜  ´−min 6= n³˜´o | 
¶
= Pr
µ
min 6=
n

³

´o
≥ 
³
˜  
´
− 
³
˜  
´
+  ¡¢ | ¶
= exp
³
− log
³

³

³
˜  
´
− 
³
˜  
´´
+ exp
¡¢´´−1
=
³

³

³
˜  
´
− 
³
˜  
´´
+ exp
¡¢´−−1 
Integrating over all possible realizations of  establishes (28).
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